Negative Signalling by Killer Ig-like Receptors

杀手 Ig 样受体的负信号传导

基本信息

  • 批准号:
    7393731
  • 负责人:
  • 金额:
    $ 28.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-07-01 至 2010-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Killer Cell Ig-like Receptors (KIR) are expressed on natural killer (NK) cells and some T cells in humans. The ligands for KIR are class I major histocompatibility complex (MHC-I) proteins expressed on virtually every cell in the body. KIR recognition of MHC-I on a normal target cell transduces a negative signal that suppresses activation events and restrains NK cells from attacking. Certain tumor cells and virus-infected cells can down regulate surface MHC-I to escape detection by cytolytic T cells. When an NK cell encounters such a mutant cell, however, the lack of KIR engagement triggers specific lysis and cytokine release toward the abnormal target. Substantial evidence implicates the protein tyrosine phosphatase (PTP), SHP-1, as a component of KIR inhibition. SHP-1 is recruited to the phosphorylated cytoplasmic domain of KIR. The molecular mechanism by which SHP-1 mediates negative signalling is unclear, however, and the prevailing view that SHP-1 mediates all inhibitory function is likely too simplistic. Our evidence clearly also implicates a related PTP, named SHP-2, in negative signalling through KIR. We propose that SHP-1 and SHP-2 are differentially recruited to KIR and that they can mediate inhibition through distinct molecular mechanisms. Identification of specific points at which each PTP disrupts NK cell activation pathways should help to delineate promising molecular targets for designing therapeutic strategies to beneficially manipulate anti-tumor and anti-viral responses by NK cells and other lymphocytes. Our future studies will define the roles of SHP-1 and SHP-2 in negative signalling through KIR by addressing the following specific aims: 1) Characterization of the kinetics of SHP-1 and SHP-2 recruitment to KIR 2) Establishment of the functional roles for SHP-1 and SHP-2 in KIR inhibition 3) Characterization of the roles of kinases in KIR inhibitory function
描述(由申请人提供):杀伤细胞Ig样受体(KIR)在人体的自然杀伤(NK)细胞和一些T细胞上表达。KIR的配体是I类主要组织相容性复合体(MHC-I)蛋白,其在体内几乎每个细胞上表达。正常靶细胞上MHC-I的KIR识别转导抑制活化事件并抑制NK细胞攻击的负信号。某些肿瘤细胞和病毒感染的细胞可以下调表面MHC-I以逃避溶细胞性T细胞的检测。然而,当NK细胞遇到这样的突变细胞时,缺乏KIR接合触发特异性裂解和细胞因子向异常靶释放。 大量证据表明蛋白酪氨酸磷酸酶(PTP),SHP-1,作为KIR抑制的一个组成部分。SHP-1被募集到KIR的磷酸化胞质结构域。然而,SHP-1介导负信号的分子机制尚不清楚,并且SHP-1介导所有抑制功能的流行观点可能过于简单化。我们的证据清楚地表明,一个相关的PTP,命名为SHP-2,通过KIR的负信号。我们建议,SHP-1和SHP-2差异招募KIR,他们可以通过不同的分子机制介导抑制。鉴定每个PTP破坏NK细胞活化途径的特定点应有助于描绘有希望的分子靶点,用于设计治疗策略以有利地操纵NK细胞和其他淋巴细胞的抗肿瘤和抗病毒应答。 我们未来的研究将通过解决以下具体目标来确定SHP-1和SHP-2在通过KIR的负信号传导中的作用: 1)SHP-1和SHP-2向KIR募集的动力学表征 2)SHP-1和SHP-2在KIR抑制中的功能作用的确立 3)激酶在KIR抑制功能中的作用的表征

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kerry S Campbell其他文献

Kerry S Campbell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kerry S Campbell', 18)}}的其他基金

Role of immune receptor clustering in controlling efficacy of antibody-dependent FcγRIIIa-mediated cytotoxicity by NK cells
免疫受体簇在控制 NK 细胞抗体依赖性 FcγRIIIa 介导的细胞毒性中的作用
  • 批准号:
    10319570
  • 财政年份:
    2020
  • 资助金额:
    $ 28.84万
  • 项目类别:
Role of immune receptor clustering in controlling efficacy of antibody-dependent FcγRIIIa-mediated cytotoxicity by NK cells
免疫受体簇在控制 NK 细胞抗体依赖性 FcγRIIIa 介导的细胞毒性中的作用
  • 批准号:
    10544158
  • 财政年份:
    2020
  • 资助金额:
    $ 28.84万
  • 项目类别:
Role of immune receptor clustering in controlling efficacy of antibody-dependent FcγRIIIa-mediated cytotoxicity by NK cells
免疫受体簇在控制 NK 细胞抗体依赖性 FcγRIIIa 介导的细胞毒性中的作用
  • 批准号:
    10078249
  • 财政年份:
    2020
  • 资助金额:
    $ 28.84万
  • 项目类别:
Understanding Psychosocial and Immunologic Responses in Indolent Lymphoproliferative Disorders
了解惰性淋巴细胞增殖性疾病的心理社会和免疫反应
  • 批准号:
    9038558
  • 财政年份:
    2016
  • 资助金额:
    $ 28.84万
  • 项目类别:
Characterization of Type-2 Cytokine-Producing NK Cells
2 型细胞因子产生 NK 细胞的表征
  • 批准号:
    8073248
  • 财政年份:
    2010
  • 资助金额:
    $ 28.84万
  • 项目类别:
Characterization of Type-2 Cytokine-Producing NK Cells
2 型细胞因子产生 NK 细胞的表征
  • 批准号:
    7860305
  • 财政年份:
    2009
  • 资助金额:
    $ 28.84万
  • 项目类别:
Characterization of Type-2 Cytokine-Producing NK Cells
2 型细胞因子产生 NK 细胞的表征
  • 批准号:
    7707072
  • 财政年份:
    2009
  • 资助金额:
    $ 28.84万
  • 项目类别:
Mechanisms of NK Cell Activation by the KIR2DL4 Receptor
KIR2DL4 受体激活 NK 细胞的机制
  • 批准号:
    7332209
  • 财政年份:
    2004
  • 资助金额:
    $ 28.84万
  • 项目类别:
Mechanisms of NK Cell Activation by the KIR2DL4 Receptor
KIR2DL4 受体激活 NK 细胞的机制
  • 批准号:
    6860141
  • 财政年份:
    2004
  • 资助金额:
    $ 28.84万
  • 项目类别:
Mechanisms of NK Cell Activation by the KIR2DL4 Receptor
KIR2DL4 受体激活 NK 细胞的机制
  • 批准号:
    7168804
  • 财政年份:
    2004
  • 资助金额:
    $ 28.84万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 28.84万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 28.84万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 28.84万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.84万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 28.84万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 28.84万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 28.84万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 28.84万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 28.84万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 28.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了